Montelukast
Always check the BNF link here before prescribing.
- ๐ Montelukast is a leukotriene receptor antagonist (LTRA).
- Used as add-on therapy in chronic asthma, particularly if symptoms are uncontrolled on inhaled corticosteroids (ICS).
- Also licensed for seasonal allergic rhinitis.
โ๏ธ Mode of Action
- Blocks CysLTโ receptors in the airway.
- โฌ๏ธ Leukotriene-mediated effects โ reduced bronchoconstriction, mucus secretion, oedema, and inflammation.
- Helps prevent exercise-induced and allergen-induced bronchospasm.
๐ Dose / Indications
- ๐ฌ๏ธ Chronic asthma prevention: 10 mg nocte (adult).
- ๐ฆ Children 6โ14 years: 5 mg chewable tablet OD.
- ๐ถ Children 6 monthsโ5 years: 4 mg granules OD (BNF guidance).
- ๐ผ Seasonal allergic rhinitis (when antihistamines are insufficient).
๐ Interactions
- See BNF for details.
- Metabolised by CYP3A4/2C9 โ potential interactions with enzyme inducers (e.g. rifampicin, phenytoin).
โ ๏ธ Cautions
- โ Not for acute asthma attacks (no bronchodilator effect).
- ๐งช ChurgโStrauss syndrome (rare): eosinophilia, neuropathy, vasculitis, rash โ typically occurs when tapering steroids.
- Use with caution in patients with psychiatric history (risk of neuropsychiatric side effects).
โ Contraindications
- See BNF โ mainly hypersensitivity to montelukast or excipients.
โ ๏ธ Side Effects
- ๐คข GI upset, nausea, diarrhoea.
- ๐ค Headache, myalgia.
- ๐ธ Rash, allergic reactions.
- ๐ง Neuropsychiatric effects (agitation, sleep disturbance, depression, suicidal thoughts โ rare but serious).
- ๐งช ChurgโStrauss syndrome (rare, associated with systemic eosinophilia).
- Dry mouth, thirst (less common).
๐ Monitoring
- Routine FEVโ and symptom control (asthma monitoring).
- Clinical vigilance for neuropsychiatric changes.
- If systemic features โ consider vasculitis screen, CXR, FBC (to assess eosinophilia).
๐ References